https://orcid.org/0000-0002-5898-0043
Key Points
DOT1L and EZH2 inhibition show synergistic antitumor effects in preclinical models of B-cell lymphoma.
Combined treatment with DOT1L and EZH2 inhibitors induced plasma cell differentiation in B-cell lymphoma.
Subjects:
Lymphoid Neoplasia
Abstract
Despite the approval of several new treatments for patients with B-cell lymphoma, there is still a large unmet need. Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are the 2 most common B-cell lymphoma subtypes, accounting for ∼50% of all cases. EZH2 heterozygous gain-of-function somatic driver mutations are frequently found in germinal center B-cell DLBCLs and FLs. An EZH2 inhibitor has shown durable responses in patients with relapsed or refractory FL, however a considerable fraction of the patients did not show an objective response. To identify alternative therapeutic strategies, we performed CRISPR/Cas9 knockout screens in B-cell lymphoma cells treated with or without an EZH2 inhibitor. This led to the identification of the histone methyltransferase DOT1L as a potential therapeutic target. Specifically, we showed that an EZH2 inhibitor synergizes with a DOT1L inhibitor in a panel of B-cell lymphoma cell lines regardless of the EZH2 mutation status. Mechanistically, we demonstrated that the 2 inhibitors cooperatively suppress DOT1L-regulated cell cycle genes, upregulate genes involved in interferon signaling, including antigen presenting genes, and ultimately drive B-cell differentiation by derepressing EZH2-regulated plasma cell signature genes. Furthermore, we demonstrated the effectiveness of this epigenetic combination strategy in a xenograft model, which led to significant abrogation of tumor growth. Together, our studies provide preclinical proof-of-concept for an epigenetic combination therapy to overcome resistance and improve durability of response for the treatment of B-cell lymphoma, warranting clinical investigation and illustrating an important convergent role of EZH2 and DOT1L in B-cell lymphomagenesis.
Subjects:
Lymphoid Neoplasia
References
1.
Thandra
KC
, Barsouk
A
, Saginala
K
, Padala
SA
, Barsouk
A
, Rawla
P
. Epidemiology of non-Hodgkin's lymphoma
. Med Sci
. 2021
;9
(1
):5
.2.
Morschhauser
F
, Tilly
H
, Chaidos
A
, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
. Lancet Oncol
. 2020
;21
(11
):1433
-1442
.3.
Morschhauser
F
, Salles
G
, Batlevi
CL
, et al. Taking the EZ way: targeting enhancer of zeste homolog 2 in B-cell lymphomas
. Blood Rev
. 2022
;56
:100988
.4.
Italiano
A
, Soria
JC
, Toulmonde
M
, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
. Lancet Oncol
. 2018
;19
(5
):649
-659
.5.
McCabe
MT
, Graves
AP
, Ganji
G
, et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)
. Proc Natl Acad Sci U S A
. 2012
;109
(8
):2989
-2994
.6.
Beguelin
W
, Popovic
R
, Teater
M
, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation
. Cancer Cell
. 2013
;23
(5
):677
-692
.7.
Laugesen
A
, Hojfeldt
JW
, Helin
K
. Molecular mechanisms directing PRC2 recruitment and H3K27 methylation
. Mol Cell
. 2019
;74
(1
):8
-18
.8.
Beguelin
W
, Rivas
MA
, Calvo Fernandez
MT
, et al. EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop
. Nat Commun
. 2017
;8
(1
):877
.9.
Beguelin
W
, Teater
M
, Gearhart
MD
, et al. EZH2 and BCL6 cooperate to assemble CBX8-BCOR complex to repress bivalent promoters, mediate germinal center formation and lymphomagenesis
. Cancer Cell
. 2016
;30
(2
):197
-213
.10.
Caganova
M
, Carrisi
C
, Varano
G
, et al. Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis
. J Clin Invest
. 2013
;123
(12
):5009
-5022
.11.
Beguelin
W
, Teater
M
, Meydan
C
, et al. Mutant EZH2 induces a pre-malignant lymphoma niche by reprogramming the immune response
. Cancer Cell
. 2020
;37
(5
):655
-673.e11
.12.
Bodor
C
, Grossmann
V
, Popov
N
, et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma
. Blood
. 2013
;122
(18
):3165
-3168
.13.
Chapuy
B
, Stewart
C
, Dunford
AJ
, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes [published correction appears in Nat Med. 2018;24(8):1290-1291]
. Nat Med
. 2018
;24
(5
):679
-690
.14.
McCabe
MT
, Ott
HM
, Ganji
G
, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
. Nature
. 2012
;492
(7427
):108
-112
.15.
Feng
Q
, Wang
H
, Ng
HH
, et al. Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain
. Curr Biol
. 2002
;12
(12
):1052
-1058
.16.
van Leeuwen
F
, Gafken
PR
, Gottschling
DE
. Dot1p modulates silencing in yeast by methylation of the nucleosome core
. Cell
. 2002
;109
(6
):745
-756
.17.
Ng
HH
, Ciccone
DN
, Morshead
KB
, Oettinger
MA
, Struhl
K
. Lysine-79 of histone H3 is hypomethylated at silenced loci in yeast and mammalian cells: a potential mechanism for position-effect variegation
. Proc Natl Acad Sci U S A
. 2003
;100
(4
):1820
-1825
.18.
Okada
Y
, Feng
Q
, Lin
Y
, et al. hDOT1L links histone methylation to leukemogenesis
. Cell
. 2005
;121
(2
):167
-178
.19.
Schubeler
D
, MacAlpine
DM
, Scalzo
D
, et al. The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote
. Genes Dev
. 2004
;18
(11
):1263
-1271
.20.
Wang
Z
, Zang
C
, Rosenfeld
JA
, et al. Combinatorial patterns of histone acetylations and methylations in the human genome
. Nat Genet
. 2008
;40
(7
):897
-903
.21.
Aslam
MA
, Alemdehy
MF
, Kwesi-Maliepaard
EM
, et al. Histone methyltransferase DOT1L controls state-specific identity during B cell differentiation
. EMBO Rep
. 2021
;22
(2
):e51184
.22.
Kealy
L
, Di Pietro
A
, Hailes
L
, et al. The histone methyltransferase DOT1L is essential for humoral immune responses
. Cell Rep
. 2020
;33
(11
):108504
.23.
Love
MI
, Huber
W
, Anders
S
. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
. Genome Biol
. 2014
;15
(12
):550
.24.
Muller
I
, Moroni
AS
, Shlyueva
D
, et al. MPP8 is essential for sustaining self-renewal of ground-state pluripotent stem cells
. Nat Commun
. 2021
;12
(1
):3034
.25.
Tsherniak
A
, Vazquez
F
, Montgomery
PG
, et al. Defining a cancer dependency map
. Cell
. 2017
;170
(3
):564
-576.e16
.26.
Stein
EM
, Garcia-Manero
G
, Rizzieri
DA
, et al. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia
. Blood
. 2018
;131
(24
):2661
-2669
.27.
Basavapathruni
A
, Olhava
EJ
, Daigle
SR
, et al. Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor
. Biopharm Drug Dispos
. 2014
;35
(4
):237
-252
.28.
Daigle
SR
, Olhava
EJ
, Therkelsen
CA
, et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
. Blood
. 2013
;122
(6
):1017
-1025
.29.
Klaus
CR
, Iwanowicz
D
, Johnston
D
, et al. DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells
. J Pharmacol Exp Ther
. 2014
;350
(3
):646
-656
.30.
Schmitz
R
, Wright
GW
, Huang
DW
, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma
. N Engl J Med
. 2018
;378
(15
):1396
-1407
.31.
Daigle
SR
, Olhava
EJ
, Therkelsen
CA
, et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
. Blood
. 2013
;122
(6
):1017
-1025
.32.
Subramanian
A
, Tamayo
P
, Mootha
VK
, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles
. Proc Natl Acad Sci U S A
. 2005
;102
(43
):15545
-15550
.33.
Hanzelmann
S
, Castelo
R
, Guinney
J
. GSVA: gene set variation analysis for microarray and RNA-seq data
. BMC Bioinf
. 2013
;14
:7
.34.
Burr
ML
, Sparbier
CE
, Chan
KL
, et al. An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer
. Cancer Cell
. 2019
;36
(4
):385
-401.e8
.35.
Zhou
L
, Mudianto
T
, Ma
X
, Riley
R
, Uppaluri
R
. Targeting EZH2 enhances antigen presentation, antitumor immunity, and circumvents anti-PD-1 resistance in head and neck cancer
. Clin Cancer Res
. 2020
;26
(1
):290
-300
.36.
Ennishi
D
, Takata
K
, Beguelin
W
, et al. Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition
. Cancer Discov
. 2019
;9
(4
):546
-563
.37.
Shaffer
AL
, Lin
KI
, Kuo
TC
, et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program
. Immunity
. 2002
;17
(1
):51
-62
.38.
Mihalcik
SA
, Huddleston
PM
, Wu
X
, Jelinek
DF
. The structure of the TNFRSF13C promoter enables differential expression of BAFF-R during B cell ontogeny and terminal differentiation
. J Immunol
. 2010
;185
(2
):1045
-1054
.39.
Kim
W
, Choi
M
, Kim
JE
. The histone methyltransferase Dot1/DOT1L as a critical regulator of the cell cycle
. Cell Cycle
. 2014
;13
(5
):726
-738
.40.
Yang
L
, Lei
Q
, Li
L
, Yang
J
, Dong
Z
, Cui
H
. Silencing or inhibition of H3K79 methyltransferase DOT1L induces cell cycle arrest by epigenetically modulating c-Myc expression in colorectal cancer
. Clin Epigenetics
. 2022
;14
(1
):67
.41.
Macrae
TA
, Fothergill-Robinson
J
, Ramalho-Santos
M
. Regulation, functions and transmission of bivalent chromatin during mammalian development
. Nat Rev Mol Cell Biol
. 2023
;24
(1
):6
-26
.42.
Isshiki
Y
, Chen
X
, Teater
M
, et al. EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function
. Cancer Cell
. 2025
;43
(1
):49
-68.e9
.43.
Herviou
L
, Jourdan
M
, Martinez
AM
, Cavalli
G
, Moreaux
J
. EZH2 is overexpressed in transitional preplasmablasts and is involved in human plasma cell differentiation
. Leukemia
. 2019
;33
(8
):2047
-2060
.44.
Duan
M
, Nguyen
DC
, Joyner
CJ
, et al. Understanding heterogeneity of human bone marrow plasma cell maturation and survival pathways by single-cell analyses
. Cell Rep
. 2023
;42
(7
):112682
.45.
Perner
F
, Gadrey
JY
, Xiong
Y
, et al. Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts
. Blood
. 2020
;136
(17
):1983
-1988
.46.
Stauffer
F
, Weiss
A
, Scheufler
C
, et al. New potent DOT1L inhibitors for in vivo evaluation in mouse
. ACS Med Chem Lett
. 2019
;10
(12
):1655
-1660
.47.
Bracken
AP
, Pasini
D
, Capra
M
, Prosperini
E
, Colli
E
, Helin
K
. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer [published correction appears in EMBO J. 2024;43(5):886]
. EMBO J
. 2003
;22
(20
):5323
-5335
.48.
Piunti
A
, Meghani
K
, Yu
Y
, et al. Immune activation is essential for the antitumor activity of EZH2 inhibition in urothelial carcinoma
. Sci Adv
. 2022
;8
(40
):eabo8043
.49.
Huang
J
, Zhang
J
, Guo
Z
, et al. Easy or not-the advances of EZH2 in regulating T cell development, differentiation, and activation in antitumor immunity
. Front Immunol
. 2021
;12
:741302
.50.
Kealy
L
, Runting
J
, Thiele
D
, Scheer
S
. An emerging maestro of immune regulation: how DOT1L orchestrates the harmonies of the immune system
. Front Immunol
. 2024
;15
:1385319
.51.
Zeng
J
, Zhang
J
, Sun
Y
, et al. Targeting EZH2 for cancer therapy: from current progress to novel strategies
. Eur J Med Chem
. 2022
;238
:114419
.© 2025 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
2025
You do not currently have access to this content.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal